Work

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

Year: 2008

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v112.11.1742.1742

Authors: Paul Richardson, Sundar Jagannath, Andrzej Jakubowiak, Sagar Lonial, Noopur Raje, Melissa Alsina, Irene Ghobrial, Amitabha Mazumder, Nikhil C Munshi, David H Vesole, Kathleen Colson, Mary L McKenney, Laura Lunde, Sarah Kennedy, Kara Kosakowski, Constantine Mitsiades, Teru Hideshima, Robert D Knight, Dixie-Lee Esseltine, Kenneth C Anderson

Institutions: Dana-Farber Cancer Institute, U-M Rogel Cancer Center, Emory University, Winship Cancer Institute, Harvard University, Massachusetts General Hospital, Moffitt Cancer Center, Celgene (United States), Takeda Oncology (United States)

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2564026069

FWCI: 6.485

Cites:

Cited by: 42

Related to: 10